Insight Molecular Diagnostics (IMDX) Non-Current Deferred Tax Liability (2019 - 2023)

Insight Molecular Diagnostics (IMDX) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $2.2 million in Q3 2023.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $2.2 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $2.2 million (changed N/A YoY) and the FY2019 annual result came in at $3.8 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability held at $2.2 million in Q3 2023 per IMDX's latest filing, from $2.2 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $3.8 million in Q4 2019, with the low at $158000.0 in Q1 2020.
• Average Non-Current Deferred Tax Liability over 3 years is $1.6 million, with a median of $2.2 million recorded in 2023.